{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:26:34Z","timestamp":1793600794432,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007761","name":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011948","name":"Abbott Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jid.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:43:14Z","timestamp":1773272594000},"page":"2504-2514.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0073-4039","authenticated-orcid":false,"given":"Mar\u00eda","family":"Olivares-Guerrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gonz\u00e1lez-Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sahuquillo-Torralba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jose-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Herrera-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-3941","authenticated-orcid":false,"given":"Ofelia","family":"Baniandr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-6411","authenticated-orcid":false,"given":"Diana P.","family":"Ruiz-Genao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Estebaranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo de la","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Mateu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Riera-Monroig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-6783","authenticated-orcid":false,"given":"Mariano","family":"Ara-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3154-7626","authenticated-orcid":false,"given":"M\u00f3nica","family":"Roncero-Riesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-2076","authenticated-orcid":false,"given":"Tamara","family":"Gracia-Caza\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Abalde-Pintos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Pujol-Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda-Donoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Del Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1341","authenticated-orcid":false,"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Su\u00e1rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0694-4757","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"D\u00edez-Madue\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Ruiz-Carrascosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lezcano-Biosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Mar\u00eda","family":"Morales-Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salgado-Boquete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Montes-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Gonz\u00e1lez-Sixto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Descalzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-1260","authenticated-orcid":false,"given":"Esteban","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.03.004_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaad.2020.08.026","article-title":"The risk of respiratory tract infections and interstitial lung disease with interleukin 12\/23 and interleukin 23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"84","author":"Akiyama","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1439-0507.2012.02170.x","article-title":"Pityriasis versicolor during anti-TNF-\u03b1 monoclonal antibody therapy: therapeutic considerations","volume":"55","author":"Balestri","year":"2012","journal-title":"Mycoses"},{"key":"10.1016\/j.jid.2026.03.004_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","article-title":"Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis","volume":"84","author":"Baniandr\u00e9s-Rodr\u00edguez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/jdv.12492","article-title":"Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry","volume":"29","author":"Carretero","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.03.004_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/myc.12200","article-title":"Influence of systemic corticotherapy on the triggering of pityriasis versicolor","volume":"57","author":"da Fraga","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.jid.2026.03.004_bib6","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2026.03.004_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","article-title":"Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry","volume":"83","author":"Daud\u00e9n","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib8","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jid.2026.03.004_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis [published correction appears in JAMA Dermatol. 2019;155:86]","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2442603","article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jid.2026.03.004_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2340\/00015555-2298","article-title":"Anogenital human papillomavirus prevalence is unaffected by therapeutic tumour necrosis factor-alpha inhibition","volume":"96","author":"Handisurya","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2026.03.004_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajd.13865","article-title":"The impact of systemic psoriasis treatments on human papillomavirus activation and propagation","volume":"63","author":"Korecka","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib17","article-title":"Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.03.004_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14261","article-title":"Apremilast in dermatology: a review of literature","volume":"33","author":"Nassim","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2026.03.004_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/jdv.20738","article-title":"Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry","volume":"39","author":"Olivares-Guerrero","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.03.004_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaad.2021.08.065","article-title":"Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts","volume":"86","author":"Pahalyants","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib21","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2021.04.036","article-title":"Assessing the risk and outcome of COVID-19 in patients with psoriasis or psoriatic arthritis on biologic treatment: a critical appraisal of the quality of the published evidence","volume":"142","author":"Piaserico","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ad.2010.10.016","article-title":"BIOBADADERM: registro espa\u00f1ol de acontecimientos adversos de terapias biol\u00f3gicas en Dermatolog\u00eda. Primer informe [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]","volume":"102","author":"Rivera","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jid.2026.03.004_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15735","article-title":"Prevalence of genital and oral human papillomavirus infection among psoriasis patients on biologic therapy","volume":"35","author":"Rob","year":"2022","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.jid.2026.03.004_bib25","doi-asserted-by":"crossref","first-page":"T764","DOI":"10.1016\/j.ad.2025.05.012","article-title":"AEDV BIOBADADERM registry: 15 year-contribution to psoriasis therapy safety","volume":"116","author":"Ruiz-Genao","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jid.2026.03.004_bib26","first-page":"964","article-title":"Effects of biologic therapies on the chance of COVID-19 infection among rheumatoid arthritis and lupus patients during the first wave of the pandemic","volume":"10","author":"Sahebari","year":"2022","journal-title":"Arch Bone Jt Surg"},{"key":"10.1016\/j.jid.2026.03.004_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib28","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.jaad.2020.03.056","article-title":"Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic","volume":"82","author":"Shah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib34","series-title":"Stata: Release 17. Statistical Software","year":"2021"},{"key":"10.1016\/j.jid.2026.03.004_bib30","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.3390\/jcm13133713","article-title":"Basic susceptibility of patients with psoriasis under systemic therapy for respiratory infections: data from the German Psoriasis Registry PsoBest","volume":"13","author":"Stephan","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jid.2026.03.004_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2020.08.095","article-title":"Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-a meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic","volume":"84","author":"Syed","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.03.004_bib32","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/jdv.18407","article-title":"Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials","volume":"36","author":"Wang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2026.03.004_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.17849","article-title":"A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis","volume":"181","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26007530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26007530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:31:45Z","timestamp":1793597505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26007530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022202X26007530"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.03.004","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules: BIOBADADERM registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Investigative Dermatology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}